1Department of Biomechanics, University of Nebraska Omaha, Omaha, NE, USA 2Omaha VA Medical Center, Omaha, NE, USA 3University of Nebraska Medical Center, Omaha, NE, USA email: bbeier@unomaha.edu web: cobre.unomaha.edu

> **Figure 2.** Pilot data of one subject's average walking economy for the last two minutes during each walking condition.

• If the exoskeleton is able to decrease the metabolic cost of walking, or the required biological torque contribution across subjects, the device may be beneficial to pathological population who exhibit

• The average walking economy for the last two minutes increased from 13.559 mL/kg/min to 14.656 mL/kg/min between the NORM

and SA conditions (8.09% increase)

DISCUSSION

• Results of this study hope to determine normative effects of the lower-leg exoskeleton on lower-limb joint angles, torques, and the

- metabolic cost of walking
- ankle weakness or reduced forward propulsion

- The ankle produces 60% of the lower-body positive mechanical work during the stance phase of gait $1,2$
- If ankle muscles are weak, there are reductions in the ability to generate appropriate torques and powers during walking
- This leads to slower preferred walking speeds (PWS), which correlate with poor physical function, more disabilities, increased hospitalization visits and costs, and even mortality $3,4$
- Due to this, many orthotic and exoskeletal devices are being created to restore proper ankle function by promoting ankle plantar flexion^{5,6}
- **Purpose:** Build a passive dynamic lower-leg exoskeleton to assist ankle plantar flexion, and assess its effects during walking
- **Hypothesis 1:** Wearing the exoskeleton will reduce the biological ankle torque contribution during stance
- **Hypothesis 2:** Wearing the exoskeleton will insignificantly affect ankle angle throughout gait
- **Hypothesis 3:** Wearing the exoskeleton will decrease the metabolic cost of walking

REFERENCES

U.S. Department
of Veterans Affairs

• Ten young, healthy participants between the ages of 19 and 35 years will walk on a level treadmill, at 10% faster than their PWS, for a variety of exoskeleton conditions (Table 1)

- All walking trials will be five minutes long and followed by a three minute rest
- Subjects will begin the study with a habituation period on the treadmill, involving three walking trials wearing the device with constant assistance actuators (CA Condition)
- 3D motion capture (Vicon Nexus) will measure hip, knee, and ankle motion in the sagittal plane
- An instrumented treadmill (Bertec) will measure ground reaction forces • Using inverse dynamics, lower-body joint torques and powers will be
- calculated from motion and force data during walking trials

- The exoskeleton assists plantar flexion at the end of the stance phase of gait, facilitating forward propulsion
- As the ankle angle changes throughout the gait cycle, there is a resulting change in the length between the clutch and the heel of the foot bracket
- During the stance phase, this stretches the spring as the heel is in contact with the ground
- As toe-off begins, the clutch releases the spring, applying a plantar flexion torque about the ankle and assisting forward propulsion

The lower-leg exoskeleton consists of four major components

MATERIALS / METHODS

Table 1. Exoskeleton conditions during level treadmill walking.

Effects of a Passive Dynamic Lower-Leg Exoskeleton during Walking Blake Beier¹, Cody Anderson¹, Anthony Arellano¹, Iraklis Pipinos^{2,3}, Sara Myers^{1,2}

INTRODUCTION

Exoskeleton Walking Conditions

Normal (No Device) – [NORM]

Exoskeleton without Elastic Actuators – [NA]

Exoskeleton with Constant Actuation – [CA]

Exoskeleton with Stance-Only Actuation – [SA]

EXOSKELETON

-
-

Figure 1. A) Schematic of the passive dynamic lower-leg exoskeleton with annotated components, and B) the exoskeleton being worn on the treadmill.

- 1. DeVita P, et al. *J Exp Biol* **210(19)**, 3361-73, 2007
- 2. Sawicki GS, et al. *Exerc Sport Sci Rev* **37(3)**, 130-8, 2009.
- 3. Winter DA, et al. *Phys Therapy* **70(6)**, 340-7, 1990.
- 4. Hardy SE, et al. *J Am Geriatr Soc* **55(11)**, 1727-34, 2007.
- 5. Malcolm P, et al. *PLoS One* **8(2)**, e56137, 2013.
- 6. Collins SH, et al. *Nature* **522(7555)**, 212-5, 2015.

This work is being supported by NIH R01AG034995, NIH R01HD090333, and UNO's Office of Research and Creative Activity UCRCA and FUSE Grants.

New Antiversity of Nebraska Medical Center

